Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX (Nasdaq: CTMX) reported positive Phase 1 expansion data for EpCAM PROBODY ADC varsetatug masetecan in late-line metastatic colorectal cancer. Confirmed ORRs were 32% at 10 mg/kg and 20% at 8.6 mg/kg; estimated median PFS was 7.1 and 6.8 months, respectively. Grade 3 diarrhea was 10% with updated prophylaxis. The company plans FDA interactions in mid-2026 and additional combination and expansion studies through 2026.
CytomX Therapeutics (Nasdaq: CTMX) will report full year 2025 financial results on March 16, 2026, before the open of U.S. markets. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT the same day.
Participants can access the live webcast and archived replay on CytomX's Events and Presentations page and are advised to register at least 10 minutes before the call.
CytomX Therapeutics (Nasdaq: CTMX) announced management will present at two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 (fireside chat at 4:30 p.m. ET) and World ADC London on Feb 25, 2026 (presentation at 5:00 p.m. GMT).
Investors can find schedules and webcast details on the company's Events and Presentations page.
CytomX (NASDAQ: CTMX) provided a 2026 business update focused on clinical milestones for its PROBODY pipeline. Varsetatug masetecan (CX-2051) Phase 1 dose expansions (7.2, 8.6, 10 mg/kg Q3W) continue, with total Phase 1 enrollment projected at ~100 patients and a Phase 1 CRC expansion update expected in Q1 2026. The company aims to align with the FDA in 2026 on a potential registrational monotherapy study and plans a Varseta-M plus bevacizumab combination study to start in Q1 2026.
CX-801 (masked interferon-alpha-2b) is in Phase 1 for advanced melanoma; monotherapy reached dose level 4 and combination dose escalation with KEYTRUDA began in May 2025, with initial combo data expected by end of 2026. Management will present at JP Morgan on January 14, 2026.
CytomX Therapeutics (NASDAQ: CTMX) announced management will present at two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 (fireside chat at 1:45 p.m. ET) in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 (fireside chat at 1:00 p.m. ET) in New York, NY.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will hold one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) said Sean McCarthy, D.Phil., chief executive officer and chairman, will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 at 9:00 a.m. GMT.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will be available for one-on-one investor meetings for registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) reported Q3 2025 results and a pipeline update on Nov 6, 2025. The company ended Q3 with $143.6 million in cash, cash equivalents and investments and expects runway to Q2 2027. Q3 revenue was $6.0 million versus $33.4 million a year earlier, driven by completion of Bristol Myers Squibb performance obligations and reduced Moderna activity. Operating expense for the quarter was $21.7 million and R&D was $15.3 million.
Pipeline highlights: CX-2051 Phase 1 expansion is ongoing, with projected enrollment of ~100 patients by a planned Phase 1 data update in Q1 2026; a CX-2051 Phase 1b combination with bevacizumab is expected to start in Q1 2026. CX-801 monotherapy biomarker data will be presented at SITC 2025 and supports ongoing combination dosing with KEYTRUDA; combo escalation began in May 2025.
CytomX Therapeutics (Nasdaq: CTMX) will present initial Phase 1 translational biomarker data for CX-801 (PROBODY interferon alpha-2b) at SITC 2025 (Nov 7–9).
Data demonstrate tumor-selective activation of interferon signaling and induction of immune cell populations and interferon-stimulated genes (including PD-1 and PD-L1) in paired tumor biopsies, and are reported as generally well tolerated in patients with metastatic melanoma refractory to prior checkpoint inhibitors. CytomX says these findings support the ongoing Phase 1 combination study of CX-801 with KEYTRUDA, with combination clinical data expected in 2026.
Poster: “Pharmacodynamic Activity of CX-801…” (Abstract 606) on Nov 8, 2025, 5:10–6:35 PM ET. Additional preclinical poster for CX-908 (Abstract 961) on Nov 7, 2025.
CytomX Therapeutics (Nasdaq: CTMX) will report its third quarter 2025 financial results on Thursday, November 6, 2025, after the close of U.S. markets.
The company will host a conference call and live webcast on November 6, 2025 at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the live webcast via the company’s Events and Presentations page and are advised to register at least 10 minutes before the call. An archived replay of the webcast will be available on the company website.
CytomX Therapeutics (Nasdaq: CTMX) on October 20, 2025 appointed Rachael Lester as Senior Vice President, Chief Business Officer to lead strategy and business development.
The company highlighted Lester’s two decades of experience in corporate strategy, partnerships and capital formation, citing prior roles as chief business officer at Replicate Bioscience, SVP of business development at Harpoon Therapeutics (acquired by Merck), and senior roles at Bruin Biometrics and Onyx Pharmaceuticals. Management said Lester will drive partnering and expand the PROBODY® platform while supporting lead clinical assets CX-2051 and CX-801 aimed at colorectal cancer and melanoma.